FINWIRES · TerminalLIVE
FINWIRES

Rothschild & Co Redburn Initiates ResMed at Neutral With $230 Price Target

By

ResMed (RMD) has an average rating of overweight and mean price target of $259.63, according to analysts polled by FactSet.

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

Related Articles